A team of surgeons at Duke University Hospital has successfully implanted a new-generation commercially-available total artificial heart, the first of such achievement in the USA. The patient was a 39-year-old man who suffered a heart failure.
The Aeson artificial heart was developed by French company CARMAT, who obtained FDA approval in the USA to enroll patients with end-stage biventricular heart failure for a study. The artificial heart uses biological valves derived from bovine tissues and operates on an external power supply.
CARMAT’s artificial heart is designed to provide a temporary device for patients waiting for heart transplant surgeries. “Because of the shortages of donor hearts, many patients die while waiting for a heart transplant,” said transplant surgeon Jacob Schroder, who led the implant procedure. “We are hopeful for new options to help these patients, many like [the patient] who have devastating disease and cannot otherwise be considered for a transplant.”
#heart #surgery #transplant #hearttransplant #transplantsurgery #artificialheart #CARMAT